Dr. Curtis has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from UCB, Centocor, Pfizer, BMS, and Abbott, and (more than $10,000 each) from Roche/Genentech, Consortium of Rheumatology Researchers of North America, Amgen, and Crescendo.
Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti–tumor necrosis factor therapy
Article first published online: 27 AUG 2012
Copyright © 2012 by the American College of Rheumatology
Arthritis Care & Research
Volume 64, Issue 9, pages 1282–1291, September 2012
How to Cite
Curtis, J. R., John, A. and Baser, O. (2012), Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti–tumor necrosis factor therapy. Arthritis Care Res, 64: 1282–1291. doi: 10.1002/acr.21693
- Issue published online: 27 AUG 2012
- Article first published online: 27 AUG 2012
- Accepted manuscript online: 13 APR 2012 12:07PM EST
- Manuscript Accepted: 28 MAR 2012
- Manuscript Received: 8 SEP 2011
- NIH. Grant Number: AR-053351
- Agency for Healthcare Research and Quality. Grant Number: R01-HS018517
Additional Supporting Information may be found in the online version of this article.
|ACR_21693_sm_SupplTable1.doc||46K||Supplementary Table 1|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.